Literature DB >> 19263096

3D pharmacophore models for thromboxane A(2) receptor antagonists.

Jing Wei1, Yixi Liu, Songqing Wang.   

Abstract

Thromboxane A(2) (TXA(2)) is an endogenous arachidonic acid derivative closely correlated to thrombosis and other cardiovascular diseases. The action of TXA(2) can be effectively inhibited with TXA(2) receptor antagonists (TXRAs). Previous studies have attempted to describe the interactions between the TXA(2) receptor and its ligands, but their conclusions are still controversial. In this study, ligand-based computational drug design is used as a new and effective way to investigate the structure-activity relationship of TXRAs. Three-dimensional pharmacophore models of TXRAs were built with HypoGenRefine and HipHop modules in CATALYST software. The optimal HypoGenRefine model was developed on the basis of 25 TXRAs. It consists of two hydrophobic groups, one aromatic ring, one hydrogen-bond acceptor and four excluded volumes. The optimal HipHop model contains two hydrophobic groups and two hydrogen-bond acceptors. These models describe the key structure-activity relationship of TXRAs, can predict their activities, and can thus be used to design novel antagonists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19263096     DOI: 10.1007/s00894-009-0475-4

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  18 in total

1.  Synthesis and biological activity of 4-methyl-3,5-dioxane derivatives as thromboxane A2 receptor antagonists.

Authors:  H Marusawa; H Setoi; A Kuroda; A Sawada; J Seki; Y Motoyama; H Tanaka
Journal:  Bioorg Med Chem       Date:  1999-11       Impact factor: 3.641

Review 2.  Thromboxane A2 receptor antagonists.

Authors:  S E Hall
Journal:  Med Res Rev       Date:  1991-09       Impact factor: 12.944

3.  Thromboxane A2: effects on airway and vascular smooth muscle.

Authors:  J Svenssen; K Strandberg; T Tuvemo; M Hamberg
Journal:  Prostaglandins       Date:  1977-09

4.  Synthesis of thromboxane receptor antagonists with bicyclo[3.1.0]hexane ring systems.

Authors:  S Kamata; N Haga; T Tsuri; K Uchida; H Kakushi; H Arita; K Hanasaki
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

5.  Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.

Authors:  P Cozzi; A Giordani; M Menichincheri; A Pillan; V Pinciroli; A Rossi; R Tonani; D Volpi; M Tamburin; R Ferrario
Journal:  J Med Chem       Date:  1994-10-14       Impact factor: 7.446

6.  Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy?

Authors:  P Gresele; E Van Houtte; J Arnout; H Deckmyn; J Vermylen
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

7.  Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.

Authors:  Michihiro Ohno; Mitsuko Miyamoto; Kazuhiro Hoshi; Takahiro Takeda; Naohiro Yamada; Atsushi Ohtake
Journal:  J Med Chem       Date:  2005-08-11       Impact factor: 7.446

8.  Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 2.

Authors:  E Ohshima; H Takami; H Sato; S Mohri; H Obase; I Miki; A Ishii; S Shirakura; A Karasawa; K Kubo
Journal:  J Med Chem       Date:  1992-09-04       Impact factor: 7.446

9.  Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.

Authors:  W A Schumacher; C L Heran; T E Steinbacher; S Youssef; M L Ogletree
Journal:  J Cardiovasc Pharmacol       Date:  1993-10       Impact factor: 3.105

10.  Design, synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor.

Authors:  Julien Hanson; Jean-Michel Dogné; Jérémie Ghiotto; Anne-Lise Moray; B Therese Kinsella; Bernard Pirotte
Journal:  J Med Chem       Date:  2007-07-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.